Qingdao Haier Biomedical Stock Working Capital
| 688139 Stock | 34.50 0.96 2.86% |
Qingdao Haier Biomedical fundamentals help investors to digest information that contributes to Qingdao Haier's financial success or failures. It also enables traders to predict the movement of Qingdao Stock. The fundamental analysis module provides a way to measure Qingdao Haier's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Qingdao Haier stock.
Qingdao |
Qingdao Haier Biomedical Company Working Capital Analysis
Qingdao Haier's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Qingdao Haier Working Capital | 1.59 B |
Most of Qingdao Haier's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Qingdao Haier Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, Qingdao Haier Biomedical has a Working Capital of 1.59 B. This is 274.57% higher than that of the Health Care Equipment & Supplies sector and 17.15% higher than that of the Health Care industry. The working capital for all China stocks is 7.86% lower than that of the firm.
Qingdao Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Qingdao Haier's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Qingdao Haier could also be used in its relative valuation, which is a method of valuing Qingdao Haier by comparing valuation metrics of similar companies.Qingdao Haier is currently under evaluation in working capital category among its peers.
Qingdao Fundamentals
| Return On Equity | 0.0816 | ||||
| Return On Asset | 0.0326 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 9.16 B | ||||
| Shares Outstanding | 317.95 M | ||||
| Shares Owned By Insiders | 40.40 % | ||||
| Shares Owned By Institutions | 33.58 % | ||||
| Price To Book | 2.55 X | ||||
| Price To Sales | 4.80 X | ||||
| Revenue | 2.28 B | ||||
| Gross Profit | 2.28 B | ||||
| EBITDA | 489.96 M | ||||
| Net Income | 406.07 M | ||||
| Total Debt | 20.8 M | ||||
| Book Value Per Share | 13.74 X | ||||
| Cash Flow From Operations | 249.26 M | ||||
| Earnings Per Share | 1.13 X | ||||
| Target Price | 80.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 10.97 B | ||||
| Total Asset | 5.53 B | ||||
| Retained Earnings | 1.86 B | ||||
| Working Capital | 1.59 B | ||||
| Net Asset | 5.53 B | ||||
| Last Dividend Paid | 0.52 |
About Qingdao Haier Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Qingdao Haier Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Qingdao Haier using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Qingdao Haier Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Qingdao Stock
Qingdao Haier financial ratios help investors to determine whether Qingdao Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Qingdao with respect to the benefits of owning Qingdao Haier security.